<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178632</url>
  </required_header>
  <id_info>
    <org_study_id>MR4009</org_study_id>
    <nct_id>NCT01178632</nct_id>
  </id_info>
  <brief_title>Therapeutic Effect of an Herbal Medicine on Anxiety</brief_title>
  <official_title>A Double-blind, Randomized, Controlled, Phase III Study of an Herbal Medicine Association for Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millet Roux</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millet Roux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, double blind, randomized study, controlled by Valeriana officinalis L for
      evaluating the efficacy of association of Passiflora incarnata L; Crataegus Oxyacantha L and
      Salix alba L. in generalized anxiety disorder. The treatment period will last four weeks and
      be followed by a post treatment visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate the clinical efficacy of the drug
      PassiflorineÂ® (Passiflora incarnata L; Crataegus Oxyacantha L and Salix alba L) compared to
      Valeriana officinalis over a period of four weeks.

      The improvement of anxiety disorders parameters (primary outcome) will be measured by the
      score of the Hamilton Anxiety Scale (HAM-A).

      Does the administration of 2 tablets a day over a period of four weeks vs. Valeriana
      officinalis lead to an improvement in anxiety disorders?
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton anxiety scale score</measure>
    <time_frame>Four weeks</time_frame>
    <description>The primary outcome measure for effectiveness will be the score of the Hamilton Anxiety Scale (HAM-A). This scale will be applied in the pre-treatment (baseline), in the two visits of the treatment and in the final visit (post-treatment). Tests will be done within groups, or between different assessments and baseline values, and intergroup comparisons, i.e. between the two treatment groups at each time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insomnia gravity index</measure>
    <time_frame>Four weeks</time_frame>
    <description>The secondary outcome measure for effectiveness will be the score of the Insomnia gravity index. This questionnaire will be applied in the pre-treatment (baseline), in the two visits of the treatment and in the final visit (post-treatment). Tests will be done within groups, or between different assessments and baseline values, and intergroup comparisons, i.e. between the two treatment groups at each time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical global impression rate scale and Patient global evaluation rate scale</measure>
    <time_frame>Four weeks</time_frame>
    <description>The other secondary outcome measure for effectiveness will be the clinical global impression rate scale and patient global evaluation rate scale. These scales will be applied in the pre-treatment (baseline), in the two visits of the treatment and in the final visit (post-treatment). Tests will be done within groups, or between different assessments and baseline values, and intergroup comparisons, i.e. between the two treatment groups at each time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Passiflora, Anxiety Disorders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet Passiflora;Crataegus;Salix; PO;BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valeriane, Anxiety Disorder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet Valeriana officinalis, PO, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Passiflora</intervention_name>
    <description>01 tablet Passiflora p.o., b.i.d.</description>
    <arm_group_label>Passiflora, Anxiety Disorders</arm_group_label>
    <other_name>PASSIFLORINE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valeriana officinalis</intervention_name>
    <description>Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.</description>
    <arm_group_label>Valeriane, Anxiety Disorder</arm_group_label>
    <other_name>VALERIANE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of generalized anxiety disorder

          -  HAM-A scale &gt; 17 and &lt;30

        Exclusion Criteria:

          -  HAM-A scale &gt; 30

          -  Psychotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARIA ELISABETE A MORAES, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CLINICAL PHARMACOLOGY UNIT - UNIFAC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MARIA ELISABETE A MORAES, MD, PhD</last_name>
    <phone>5585-32232903</phone>
    <email>betemora@matrix.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit - Unifac</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <zip>60430-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>MARIA ELISABETE A MORAES, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ALEXANDRE AQUINO CAMARA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed</url>
    <description>ANXIETY DISORDERS</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed</url>
    <description>Passion Flower</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed</url>
    <description>Valeriana officinalis</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2010</study_first_submitted>
  <study_first_submitted_qc>August 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <last_update_submitted>August 9, 2010</last_update_submitted>
  <last_update_submitted_qc>August 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>FRANCISCO ALVES BORGES</name_title>
    <organization>MILLET ROUX</organization>
  </responsible_party>
  <keyword>Herbal</keyword>
  <keyword>Phytotherapy</keyword>
  <keyword>Passiflora</keyword>
  <keyword>Valeriana</keyword>
  <keyword>Anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

